MLTX (MoonLake Immunotherapeutics) Tariff Resilience Score: 8/10 (As of Jun. 29, 2026)


MLTX MoonLake Immunotherapeutics MLTX
30 GF Score
Price $19.90
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Tariff Resilience Score?

MoonLake Immunotherapeutics MLTX -0.55% 30 Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus rates MLTX with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,375 Biotechnology companies, MoonLake Immunotherapeutics ranks better than 98.69% on this metric.

MoonLake Immunotherapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

MoonLake Immunotherapeutics has Biotech company with limited exposure to tariffs due to focus on R&D and intellectual property. Can adjust pricing and has flexibility in sourcing, reducing tariff impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MoonLake Immunotherapeutics might have Highly Resilient.

MoonLake Immunotherapeutics  (NAS:MLTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MoonLake Immunotherapeutics Tariff Resilience Score Related Terms

MLTX vs FTRE, SEPN, URGN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Tariff Resilience Score falls into.


MLTX
30GF Score
MoonLake Immunotherapeutics MLTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
MoonLake Immunotherapeutics (MLTX) has a Tariff Resilience Score of 8 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is MoonLake Immunotherapeutics' Tariff Resilience Score too high?
MoonLake Immunotherapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. MoonLake Immunotherapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, MoonLake Immunotherapeutics ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Tariff Resilience Score compare to FTRE and SEPN?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #18 out of 1375 companies for Tariff Resilience Score. This places MoonLake Immunotherapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. MoonLake Immunotherapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MoonLake Immunotherapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MLTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.90
Price